Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 11/20 | 0.41 |
| ▸ | MMP8 | P22894 | 4/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25527039 | 0.89 | MMP8 (0.41) | CA12CA1CA9RORCMMP8 | |
| SCHEMBL25529194 | 0.87 | CA12 (0.42) | CA12CA1CA9RORCMMP8 | |
| SCHEMBL28913061 | 0.80 | HCRTR1 (0.38) | CA12CA1CA9RORCHCRTR1 | |
| SCHEMBL25529191 | 0.78 | CA12 (0.42) | CA12CA1CA9RORCMMP8 | |
| SCHEMBL25526833 | 0.77 | CA1 (0.43) | CA12CA1CA9RORCMMP8 | |
| SCHEMBL29973632 | 0.77 | CA1 (0.43) | CA12CA1CA9RORCMMP8 | |
| SCHEMBL25525988 | 0.77 | CA1 (0.43) | CA12CA1CA9MMP8MMP3 | |
| SCHEMBL25527143 | 0.75 | CA1 (0.41) | CA12CA1CA9RORCMMP8 | |
| SCHEMBL12145454 | 0.73 | CA1 (0.48) | CA12CA1CA9HDAC3HDAC1 | |
| SCHEMBL2178849 | 0.73 | ALDH1A1 (0.56) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-115814095-A | Combination of RAD51 inhibitors and anti-cancer therapeutics | 江苏先声药业有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115707702-A | Crystal forms of RAD51 inhibitor compounds and uses thereof | 江苏先声药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-115315423-A | Substituted aryl compounds | 先声药业有限公司 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | CA12 4875/4885CA1 4865/4885CA9 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.